EVAX 6-K Reveals New Streptococcus Vaccine Initiative, Expanding R&D

Rhea-AI Filing Summary

Evaxion (NASDAQ: EVAX) filed a Form 6-K furnishing a June 25, 2025 press release entitled “Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus.” The document reports that the clinical-stage TechBio company is adding a Group A Strep prophylactic candidate to its AI-Immunology-powered vaccine portfolio.

The submission is informational only: it contains no financial statements, guidance, capital-raising details, or clinical timelines. The press release (Exhibit 99.1) is incorporated by reference into multiple outstanding registration statements (Forms S-8, F-1 and F-3), ensuring that future prospectuses automatically reflect the new program.

There are no disclosures of changes in management, litigation, risk factors, or business strategy beyond the stated pipeline expansion. Accordingly, the filing signals strategic breadth but offers limited quantifiable data for investors to model near-term cash requirements or milestones.

Positive

• Announcement of a new vaccine program targeting Group A Streptococcus, broadening Evaxion’s AI-driven infectious disease pipeline

Negative

• None.

Insights

Biotech Analyst

TL;DR: Pipeline grows; no economics disclosed—directionally positive but too early for valuation impact.

The 6-K indicates Evaxion has initiated a vaccine program against Group A Streptococcus, a pathogen responsible for significant global morbidity. Expanding the portfolio strengthens the strategic narrative that the AI-Immunology platform can address multiple infectious targets. Because the filing is silent on development stage, cost, or partnering structure, investors cannot yet quantify NPV or dilution effects. Nevertheless, adding a new antigen class modestly improves optionality and could broaden the addressable market if clinical data emerge. In the absence of financial detail, the disclosure appears primarily reputational, suggesting upside optionality rather than immediate balance-sheet impact.

Risk Analyst

TL;DR: Opportunity offset by execution risk; cash-flow implications undisclosed.

While a new vaccine candidate diversifies the pipeline, Evaxion provides no information on incremental R&D spend, regulatory path, or funding sources. Given that early-stage vaccine programs often require multi-year investment before value inflection, the omission limits visibility into future cash burn and potential financing needs. The incorporation into existing registration statements hints at the possibility of follow-on equity usage, but that is not expressly stated. Overall risk profile remains unchanged until the company clarifies development timelines and capital allocation.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On June 25, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: June 25, 2025		By:	/s/ Christian Kanstrup
			Christian Kanstrup
			Chief Executive Officer

FAQ

What did EVAX disclose in its June 2025 Form 6-K?

The company furnished a press release announcing a new vaccine program for Group A Streptococcus and attached it as Exhibit 99.1.

Does the 6-K include any financial results for EVAX?

No. The filing contains no financial statements, guidance, or funding details; it is solely an informational update on R&D activities.

Which exhibit accompanies the EVAX 6-K filing?

Exhibit 99.1—press release titled “Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus.”

Under which form does EVAX file its annual report?

The check-mark box confirms EVAX files annual reports under Form 20-F.

Was there any change in EVAX’s management disclosed?

No. The 6-K reports no management or board changes.